Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Sunesis Pharmaceuticals (SNSS) has received an alarming one-star ranking.
With that in mind, let's take a closer look at Sunesis and see what CAPS investors are saying about the stock right now.
Sunesis facts
|
Headquarters (founded) |
South San Francisco, Calif. (1998) |
|
Market Cap |
$280.8 million |
|
Industry |
Biotechnology |
|
Trailing-12-Month Revenue |
$5.7 million |
|
Management |
CEO Daniel Swisher Jr. (since 2004) |
|
Return on Capital (average, past 3 years) |
(61.2%) |
|
Cash/Debt |
$61.0 million / $23.8 million |
|
Competitors |
AstraZeneca |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 30% of the 96 members who have rated Sunesis believe the stock will underperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star zzlangerhans, succinctly summed up the bear case for our ommunity:
Sunesis seems to have settled into a tight trading range since March, and I see [$5.50 per share] as a good trigger to set an underperform so as to take maximal advantage of the fluctuations. I'll likely stick with red thumbs because I think the stock is massively overvalued considering the negative implications of the 2012 interim analysis, which I delineated in one of my previous underperform pitches. As of now, topline data from the VALOR trial is expected in H1 2014 and I'm hoping for a huge upward run that will make puts enormously profitable.
